Acthar Gel ( DrugBank: - )
6 diseases
ID | Disease name (Link within this page) | Number of trials |
---|---|---|
13 | Multiple sclerosis/Neuromyelitis optica | 7 |
46 | Malignant rheumatoid arthritis | 4 |
49 | Systemic lupus erythematosus | 2 |
50 | Dermatomyositis | 1 |
84 | Sarcoidosis | 7 |
222 | Primary nephrotic syndrome | 3 |
13. Multiple sclerosis/Neuromyelitis optica
Clinical trials : 3,342 / Drugs : 2,355 - (DrugBank : 406) / Drug target genes : 269 - Drug target pathways : 241
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT01950234 (ClinicalTrials.gov) | October 2013 | 30/8/2013 | ACTH in Progressive Forms of MS | Treatment of Progressive Forms of Multiple Sclerosis With Pulsed ACTH (Acthar Gel) | Secondary Progressive Multiple Sclerosis;Primary Progressive Multiple Sclerosis;Progressive Relapsing Multiple Sclerosis | Drug: ACTH;Drug: Placebo | University of Minnesota | Mallinckrodt | Active, not recruiting | 18 Years | N/A | All | 100 | Phase 2 | United States |
2 | NCT01906684 (ClinicalTrials.gov) | August 2013 | 19/7/2013 | Comprehensive Analysis of Relapse in Multiple Sclerosis | Comprehensive Analysis of Relapse in Multiple Sclerosis | Multiple Sclerosis | Drug: Acthar Gel | Tanner Foundation for Multiple Sclerosis | Questcor Pharmaceuticals, Inc.;Auburn University MRI Research Center;iReportoire Inc | Not yet recruiting | 19 Years | 65 Years | Both | 20 | N/A | United States |
3 | NCT02290444 (ClinicalTrials.gov) | August 2013 | 23/10/2014 | Effects of Acthar on Recovery From Cognitive Relapses in MS | Effects of Adrenocorticotropic Hormone (ACTHAR Gel) on Recovery From Cognitive Relapses in Multiple Sclerosis | Multiple Sclerosis | Drug: Adrenocorticotropic Hormone | State University of New York at Buffalo | NULL | Completed | 18 Years | 65 Years | All | 64 | Phase 3 | United States |
4 | NCT01900093 (ClinicalTrials.gov) | July 2013 | 11/7/2013 | Evaluation of the Response to Acthar Gel Therapy in Patients Who Failed Intravenous Methylprednisolone (IVMP) for MS Relapses | An Open-Label Prospective Proof-Of-Concept Trial to Evaluate the Response to Acthar Gel Therapy in Patients With Multiple Sclerosis (MS) Relapses Who Have Failed To Make an Adequate Recovery After Treatment With High-Dose Intravenous Methylprednisolone | Multiple Sclerosis | Drug: Acthar Gel | Aaron Miller | Mallinckrodt | Recruiting | 18 Years | 65 Years | All | 10 | N/A | United States |
5 | NCT01838174 (ClinicalTrials.gov) | May 2013 | 18/4/2013 | A Trial of Neuroprotection With ACTH in Acute Optic Neuritis | A Phase IV Trial of Neuroprotection With ACTH in Acute Optic Neuritis | Multiple Sclerosis | Drug: ACTHAR Gel (ACTH);Drug: IV methylprednisolone (steroids) | University of Colorado, Denver | Mallinckrodt;University of Pennsylvania | Terminated | 18 Years | 55 Years | All | 100 | Phase 4 | United States |
6 | NCT01888354 (ClinicalTrials.gov) | April 2013 | 16/5/2013 | Pilot Clinical Trial of ACTHar Gel 14 Days Subcutaneous (SQ)Versus ACTHar Gel Five Days SQ for the Treatment of MS Exacerbations | Pilot Clinical Trial of ACTHar Gel 14 Days Subcutaneous (SQ) Versus ACTHar Gel Five Days SQ for the Treatment of MS Exacerbations | Multiple Sclerosis (MS) | Drug: H.P. Acthar Gel (repository corticotropin injection) | The University of Texas Health Science Center, Houston | NULL | Completed | 18 Years | 55 Years | Both | 25 | Phase 4 | United States |
7 | NCT01049451 (ClinicalTrials.gov) | November 2009 | 13/1/2010 | Pulse ACTH vs. MP for MS | Comparison of Monthly Pulse ACTH (Acthar Gel) Therapy With Methylprednisolone (MP, Solumedrol) for Long-Term Treatment of Multiple Sclerosis (MS) as an Add on Therapy to Beta-interferons (Avonex, Betaseron or Rebif) | Multiple Sclerosis | Drug: ACTH;Drug: Methylprednisolone | University of Southern California | NULL | Completed | 18 Years | 65 Years | All | 23 | Phase 1 | United States |
46. Malignant rheumatoid arthritis
Clinical trials : 4,325 / Drugs : 2,671 - (DrugBank : 417) / Drug target genes : 187 - Drug target pathways : 224
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT03082573 (ClinicalTrials.gov) | March 3, 2017 | 13/3/2017 | Efficacy, Radiographic and Laboratory Changes in Refractory Rheumatoid Arthritis Patients Treated With H.P. Acthar Gel | Open-label, Pilot Protocol of Patients With Rheumatoid Arthritis Who Were Treated With H.P. Acthar Gel After an Incomplete Response to Combinations of DMARDs and Biologic DMRADs | Rheumatoid Arthritis | Drug: H.P. Acthar gel | Iraj Sabahi Research Inc. | Mallinckrodt | Recruiting | 21 Years | N/A | All | 30 | Phase 4 | United States |
2 | NCT02919761 (ClinicalTrials.gov) | November 7, 2016 | 26/9/2016 | Safety and Effectiveness of Acthar Gel in Participants With Rheumatoid Arthritis | A Multicenter, 2 Part Study to Assess the Efficacy and Safety of Acthar Gel in Subjects With Rheumatoid Arthritis With Persistently Active Disease Despite Dual-DMARD Treatment | Arthritis, Rheumatoid | Drug: Acthar Gel;Drug: Placebo | Mallinckrodt | NULL | Completed | 18 Years | N/A | All | 259 | Phase 4 | United States;Argentina;Mexico;Peru;Puerto Rico;Colombia |
3 | NCT02030028 (ClinicalTrials.gov) | November 2014 | 6/1/2014 | ACTH Gel Therapy in Rheumatoid Arthritis | Open Label Study to Evaluate Efficacy and Safety of Short-Term, Adjunctive Adrenocorticotropic Hormone (ACTH) Gel in Rheumatoid Arthritis | Rheumatoid Arthritis | Drug: ACTHAR gel | Dana Ascherman | Mallinckrodt | Recruiting | 18 Years | 100 Years | All | 20 | N/A | United States |
4 | NCT02434757 (ClinicalTrials.gov) | February 2014 | 30/4/2015 | Addition of H.P. Acthar Gel to Treatment Regimen of Patients With Rheumatoid Arthritis | Addition of H. P Acthar Gel to Treatment Regimen of Patients With Rheumatoid Arthritis Inadequately Controlled With Biologic Disease-Modifying Antirheumatic Drugs | Rheumatoid Arthritis | Drug: H.P. Acthar Gel | Ronald J. Rapoport, MD | Questcor Pharmaceuticals, Inc. | Recruiting | 18 Years | N/A | Both | 10 | N/A | United States |
49. Systemic lupus erythematosus
Clinical trials : 946 / Drugs : 722 - (DrugBank : 186) / Drug target genes : 117 - Drug target pathways : 199
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT02953821 (ClinicalTrials.gov) | December 16, 2016 | 1/11/2016 | Acthar Gel for Active Systemic Lupus Erythematosus (SLE) | A Multicenter, Randomized, Double Blind, Placebo Controlled Study to Assess the Efficacy and Safety of Acthar Gel in Subjects With Persistently Active Systemic Lupus Erythematosus Despite Moderate Dose Corticosteroids | Lupus Erythematosus, Systemic | Drug: Acthar Gel;Drug: Placebo Gel | Mallinckrodt | NULL | Completed | 18 Years | N/A | All | 172 | Phase 4 | United States;Argentina;Chile;Mexico;Peru;Colombia |
2 | NCT01769937 (ClinicalTrials.gov) | October 2012 | 15/1/2013 | Open-label Trial of Acthar Gel in Subjects With Moderate to Severe Active Systemic Lupus Erythematosus | A Single-site, Investigator Initiated Open-Label Trial of H.P. Acthar Gel (Repository Corticotropin Injection)an Adrenocorticotropic Hormone (ACTH) Analogue in Subjects With Moderately to Severely Active Systemic Lupus Erythematosus (SLE) | Lupus Erythematosus Systemic Exacerbation | Drug: H.P. Acthar Gel | Fiechtner, Justus J., M.D., P.C. | NULL | Completed | 18 Years | 75 Years | Both | 10 | Phase 4 | United States |
50. Dermatomyositis
Clinical trials : 182 / Drugs : 229 - (DrugBank : 88) / Drug target genes : 48 - Drug target pathways : 147
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT02245841 (ClinicalTrials.gov) | June 15, 2015 | 11/9/2014 | Efficacy and Safety of H.P. Acthar Gel for the Treatment of Refractory Cutaneous Manifestations of Dermatomyositis | Efficacy and Safety of H.P. Acthar Gel for the Treatment of Refractory Cutaneous Manifestations of Dermatomyositis | Dermatomyositis;Juvenile Dermatomyositis | Drug: H.P. Acthar Gel | The Cleveland Clinic | Mallinckrodt | Completed | 18 Years | N/A | All | 15 | Phase 4 | United States |
84. Sarcoidosis
Clinical trials : 149 / Drugs : 227 - (DrugBank : 81) / Drug target genes : 82 - Drug target pathways : 167
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT02523092 (ClinicalTrials.gov) | October 2020 | 10/8/2015 | Use of CXCL9 as a Biomarker of Acthar Efficacy | Use of CXCL9 as a Biomarker of Acthar Efficacy | Sarcoidosis | Drug: Acthar gel | University of California, San Francisco | Mallinckrodt | Not yet recruiting | 18 Years | 65 Years | All | 14 | Phase 4 | United States |
2 | NCT03320070 (ClinicalTrials.gov) | February 21, 2018 | 20/10/2017 | Acthar Gel in Participants With Pulmonary Sarcoidosis | A Phase 4, Multicenter, Randomized, Double Blind, Placebo Controlled Pilot Study to Assess the Efficacy and Safety of Acthar Gel in Subjects With Pulmonary Sarcoidosis | Sarcoidosis, Pulmonary | Drug: Acthar Gel;Drug: Placebo | Mallinckrodt | NULL | Completed | 18 Years | 90 Years | All | 55 | Phase 4 | United States |
3 | NCT02725177 (ClinicalTrials.gov) | July 2016 | 11/3/2016 | Ocular Sarcoidosis Open Label Trial of ACTHAR Gel | Ocular Sarcoidosis Open Label Trial of ACTHAR Gel | Ocular Sarcoidosis;Panuveitis;Anterior Uveitis | Drug: Repository Corticotropin Injection;Drug: Repository Corticotropin Injection -Treatment Extension | The Cleveland Clinic | Mallinckrodt | Recruiting | 18 Years | 99 Years | All | 20 | N/A | United States |
4 | NCT02298491 (ClinicalTrials.gov) | May 2016 | 14/11/2014 | CNS Sarcoidosis and Acthar Gel | Clinical Biomarkers of Disease Activity and Treatment Responses in Patients With CNS Sarcoidosis Treated With H.P. Acthar Gel | CNS Sarcoidosis | Drug: H.P. Acthar Gel | University of Maryland, Baltimore | Mallinckrodt | Completed | N/A | N/A | All | 4 | Phase 4 | United States |
5 | NCT02348905 (ClinicalTrials.gov) | March 2015 | 20/6/2014 | ACTHAR Gel for Cutaneous Sarcoidosis: An Open Label Trial | ACTHAR Gel for Cutaneous Sarcoidosis: An Open Label Trial | Sarcoidosis;Cutaneous Sarcoidosis | Drug: ACTHAR Gel 40 units twice weekly;Drug: ACTHAR Gel 80 units twice weekly. | Albany Medical College | NULL | Not yet recruiting | 18 Years | N/A | Both | 10 | Phase 2/Phase 3 | United States |
6 | NCT02155803 (ClinicalTrials.gov) | February 2015 | 30/5/2014 | ACTHAR GEL for Sarcoidosis-Associated Calcium Dysregulation: An Open-label Pilot Study | ACTHAR GEL for Sarcoidosis-Associated Calcium Dysregulation: An Open-label Pilot Study | Sarcoidosis;Hypercalcemia Due to Sarcoidosis | Drug: ACTHAR Gel (adrenocorticotropic hormone) | Albany Medical College | NULL | Not yet recruiting | 18 Years | N/A | Both | 10 | Phase 2/Phase 3 | United States |
7 | NCT02188017 (ClinicalTrials.gov) | June 2014 | 24/4/2014 | Acthar Gel for Chronic Pulmonary Sarcoidosis (ACPS) | ACTHAR Gel for Chronic Pulmonary Sarcoidosis (ACPS) | Sarcoidosis;Pulmonary Sarcoidosis | Drug: Acthar gel | University of Cincinnati | Mallinckrodt | Recruiting | 18 Years | 90 Years | Both | 20 | Phase 4 | United States |
222. Primary nephrotic syndrome
Clinical trials : 285 / Drugs : 285 - (DrugBank : 108) / Drug target genes : 62 - Drug target pathways : 191
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT02633046 (ClinicalTrials.gov) | October 10, 2016 | 15/12/2015 | Acthar for Treatment-Resistant or Treatment-Intolerant Proteinuria | Treatment of Proteinuria Due to Treatment Resistant or Treatment Intolerant Idiopathic Focal Segmental Glomerulosclerosis: A Prospective Study of Acthar (PODOCYTE) | Idiopathic Focal Segmental Glomerulosclerosis | Drug: Acthar Gel | Mallinckrodt ARD LLC | NULL | Completed | 18 Years | N/A | All | 63 | Phase 4 | United States;Argentina;Australia;Chile;Mexico;Peru;Turkey;Canada;Hong Kong;New Zealand;Puerto Rico |
2 | NCT01386554 (ClinicalTrials.gov) | August 2011 | 29/6/2011 | Acthar for Treatment of Proteinuria in Membranous Nephropathy Patients | A Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Study of H.P. Acthar Gel (Acthar) in Treatment-Resistant Subjects With Persistent Proteinuria and Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy (iMN) | Proteinuria;Idiopathic Membranous Nephropathy | Drug: Repository Corticotropin Injection;Drug: Placebo | Mallinckrodt | NULL | Completed | 18 Years | N/A | All | 60 | Phase 4 | United States;Canada;Chile;Mexico;Turkey |
3 | NCT01155141 (ClinicalTrials.gov) | September 2009 | 29/6/2010 | Idiopathic Focal Segmental Glomerulosclerosis (FSGS) and Treatment With ACTH | Idiopathic Focal Segmental Glomerulosclerosis (FSGS) and Treatment With ACTH | Kidney Diseases | Drug: H.P. Acthar Gel | Stanford University | Mallinckrodt | Completed | 16 Years | 65 Years | All | 15 | Phase 4 | United States |